Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Rapid drug susceptibility testing with a molecular beacon assay is associated with earlier diagnosis and treatment of multidrug-resistant tuberculosis in California.

Banerjee R, Allen J, Lin SY, Westenhouse J, Desmond E, Schecter GF, Scott C, Raftery A, Mase S, Watt JP, Flood J.

J Clin Microbiol. 2010 Oct;48(10):3779-81. doi: 10.1128/JCM.01236-10. Epub 2010 Aug 11.

2.

Advances in rapid diagnosis of tuberculosis disease and anti-tuberculous drug resistance.

Alcaide F, Coll P.

Enferm Infecc Microbiol Clin. 2011 Mar;29 Suppl 1:34-40. doi: 10.1016/S0213-005X(11)70016-7. Review.

PMID:
21420565
3.

Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing.

Kalokhe AS, Shafiq M, Lee JC, Ray SM, Wang YF, Metchock B, Anderson AM, Nguyen ML.

Am J Med Sci. 2013 Feb;345(2):143-8. doi: 10.1097/MAJ.0b013e31825d32c6. Review.

4.

Detection of drug resistance in Mycobacterium tuberculosis: Methods, principles and applications.

Gupta A, Anupurba S.

Indian J Tuberc. 2015 Jan;62(1):13-22. doi: 10.1016/j.ijtb.2015.02.003. Epub 2015 Mar 20. Review.

PMID:
25857561
5.

Microscopic-observation drug susceptibility and thin layer agar assays for the detection of drug resistant tuberculosis: a systematic review and meta-analysis.

Minion J, Leung E, Menzies D, Pai M.

Lancet Infect Dis. 2010 Oct;10(10):688-98. doi: 10.1016/S1473-3099(10)70165-1. Epub 2010 Aug 31. Review.

PMID:
20813587
6.

Fighting an old disease with modern tools: characteristics and molecular detection methods of drug-resistant Mycobacterium tuberculosis.

Engström A.

Infect Dis (Lond). 2016;48(1):1-17. doi: 10.3109/23744235.2015.1061205. Epub 2015 Jul 13. Review.

PMID:
26167849
7.

[Management of multidrug-resistant tuberculosis].

Tritar F, Daghfous H, Ben Saad S, Slim-Saidi L.

Rev Pneumol Clin. 2015 Apr-Jun;71(2-3):130-9. doi: 10.1016/j.pneumo.2014.05.001. Epub 2014 Aug 19. Review. French.

PMID:
25153927
8.

Rapid diagnostics of tuberculosis and drug resistance in the industrialized world: clinical and public health benefits and barriers to implementation.

Drobniewski F, Nikolayevskyy V, Maxeiner H, Balabanova Y, Casali N, Kontsevaya I, Ignatyeva O.

BMC Med. 2013 Aug 29;11:190. doi: 10.1186/1741-7015-11-190. Review.

9.

Alternative methods of diagnosing drug resistance--what can they do for me?

Moore DA, Shah NS.

J Infect Dis. 2011 Nov 15;204 Suppl 4:S1110-9. doi: 10.1093/infdis/jir448. Review.

10.

Innovations in Tuberculosis Diagnostics: Progress and Translational Challenges.

Pai M.

EBioMedicine. 2015 Jan 31;2(3):182-3. doi: 10.1016/j.ebiom.2015.01.018. eCollection 2015 Mar. Review. No abstract available.

11.

Impact of Molecular Diagnostics for Tuberculosis on Patient-Important Outcomes: A Systematic Review of Study Methodologies.

Schumacher SG, Sohn H, Qin ZZ, Gore G, Davis JL, Denkinger CM, Pai M.

PLoS One. 2016 Mar 8;11(3):e0151073. doi: 10.1371/journal.pone.0151073. eCollection 2016. Review.

12.

Target product profile of a molecular drug-susceptibility test for use in microscopy centers.

Denkinger CM, Dolinger D, Schito M, Wells W, Cobelens F, Pai M, Zignol M, Cirillo DM, Alland D, Casenghi M, Gallarda J, Boehme CC, Perkins MD.

J Infect Dis. 2015 Apr 1;211 Suppl 2:S39-49. doi: 10.1093/infdis/jiu682. Review.

Supplemental Content

Support Center